Literature DB >> 22521815

Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.

Y Tizabi1, B H Bhatti, K F Manaye, J R Das, L Akinfiresoye.   

Abstract

Preclinical as well as limited clinical studies indicate that ketamine, a non-competitive glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, may exert a quick and prolonged antidepressant effect. It has been postulated that ketamine action is due to inhibition of NMDA and stimulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. Here, we sought to determine whether ketamine would exert antidepressant effects in Wistar-Kyoto (WKY) rats, a putative animal model of depression and whether this effect would be associated with changes in AMPA/NMDA receptor densities in the hippocampus. Adult female WKY rats and their control Wistar rats were subjected to acute and chronic ketamine doses and their locomotor activity (LMA) and immobility in the forced swim test (FST) were evaluated. Hippocampal AMPA and NMDA receptor densities were also measured following a chronic ketamine dose. Ketamine, both acutely (0.5-5.0 mg/kg i.p.) and chronically (0.5-2.5 mg/kg daily for 10 days) resulted in a dose-dependent and prolonged decrease in immobility in FST in WKY rats only, suggesting an antidepressant-like effect in this model. Chronic treatment with an effective dose of ketamine also resulted in an increase in AMPA/NMDA receptor density ratio in the hippocampus of WKY rats. LMA was not affected by any ketamine treatment in either strain. These results indicate a rapid and lasting antidepressant-like effect of a low ketamine dose in WKY rat model of depression. Moreover, the increase in AMPA/NMDA receptor density in the hippocampus could be a contributory factor to behavioral effects of ketamine. These findings suggest potential therapeutic benefit in simultaneous reduction of central NMDA and elevation of AMPA receptor function in treatment of depression.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521815      PMCID: PMC3367052          DOI: 10.1016/j.neuroscience.2012.03.052

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  Ketamine and the potential role for rapid-acting antidepressant medications.

Authors:  John H Krystal
Journal:  Swiss Med Wkly       Date:  2007-04-21       Impact factor: 2.193

Review 2.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

3.  Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence.

Authors:  R C Kessler; K A McGonagle; M Swartz; D G Blazer; C B Nelson
Journal:  J Affect Disord       Date:  1993 Oct-Nov       Impact factor: 4.839

4.  Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.

Authors:  Nagahisa Okamoto; Tetsuji Nakai; Kota Sakamoto; Yuko Nagafusa; Teruhiko Higuchi; Toru Nishikawa
Journal:  J ECT       Date:  2010-09       Impact factor: 3.635

Review 5.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

6.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

7.  Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits.

Authors:  Wulf Hevers; Stephen H Hadley; Hartmut Lüddens; Jahanshah Amin
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice.

Authors:  Sijie Tan; John A Rudd; David T Yew
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  66 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

3.  Structural and Functional Plasticity within the Nucleus Accumbens and Prefrontal Cortex Associated with Time-Dependent Increases in Food Cue-Seeking Behavior.

Authors:  Paige M Dingess; Rebecca A Darling; Rifka C Derman; Shaun S Wulff; Melissa L Hunter; Carrie R Ferrario; Travis E Brown
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

Review 4.  Pathogenesis of depression: Insights from human and rodent studies.

Authors:  C Ménard; G E Hodes; S J Russo
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  Corticosterone mediates the synaptic and behavioral effects of chronic stress at rat hippocampal temporoammonic synapses.

Authors:  Mark D Kvarta; Keighly E Bradbrook; Hannah M Dantrassy; Aileen M Bailey; Scott M Thompson
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

6.  Pharmaco-electroencephalographic responses in the rat differ between active and inactive locomotor states.

Authors:  Ingeborg H Hansen; Claus Agerskov; Lars Arvastson; Jesper F Bastlund; Helge B D Sørensen; Kjartan F Herrik
Journal:  Eur J Neurosci       Date:  2019-04-01       Impact factor: 3.386

Review 7.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

8.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

9.  Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2014-05-06       Impact factor: 13.382

Review 10.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.